Sermonix Pharmaceuticals convened the inaugural meeting of its Oncology Steering Committee July 14th 2016 in New York City. The group, which included world-renowned experts focused on the prevention, diagnosis and treatment of breast cancer, discussed the utility of Sermonix’s lead investigational drug, lasofoxifene, in breast cancer treatment and survivorship.

“Sermonix is engaging with some of the leading experts in the management of breast cancer patients and survivors, and the input we received at our meeting was invaluable,” said Dr. David Portman, Chief Executive Officer and Chief Medical Officer of Sermonix. “Sermonix looks forward to contributing to this important therapeutic area and exploring other uses for lasofoxifene in the oncology space with the ongoing guidance from this esteemed group of researchers and clinicians.”

The Sermonix Oncology Steering Committee members are:

Sarat Chandarlapaty, MD, PhD, Laboratory/Clinical Oncologist developing new treatments for resistant breast cancers, Memorial Sloan-Kettering Cancer Center


Matthew Ellis, MD: Director of the Lester and Sue Smith Breast Center at Baylor College of Medicine


Shari Goldfarb, M.D: Medical Oncologist, Memorial Sloan Kettering Cancer Center


Geoffrey Greene, PhD: Virginia and D.K. Ludwig Professor and Chair, The Ben May Department of Cancer Research, Professor, Department of Biochemistry and Molecular Biology, Co-Director, Ludwig Center for Metastasis Research


Rinath Jeselsohn, MDClinical and Research Oncologist Dana-Farber Cancer Institute, Instructor in Medicine, Harvard Medical School


Michael Krychman, MD: Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine in Newport Beach, California; Medical Director, Sexual Medicine, Hoag Hospital, Newport Beach, California


Larry Norton, MD: Deputy Physician-in-Chief for Breast Cancer Programs at Memorial Sloan Kettering Cancer Center; Medical Director of the Evelyn H. Lauder Breast Center; Norna S. Sarofim Chair in Clinical Oncology; Breast Cancer Research Foundation Scientific Director


Richard Santen, MD: Professor of Medicine: Endocrinology and Metabolism, University of Virginia School of Medicine. Immediate Past-President, The Endocrine Society. Research interests include the development of aromatase inhibitors for treatment of breast cancer, mechanisms relating estrogens to breast cancer, and the biology of endocrine-dependent breast cancer.